Induction of mucosal and systemic immune response by oral immunization with H. pylori lysates encapsulated in poly(D,L-lactide-co-glycolide) microparticles

Vaccine

Volumn 17, Issue 6, 1999, Pages 607-616

  Kim, S Y ^a   Doh, H J ^a   Ahn, J S ^a   Ha, Y J ^a   Jang, M H ^a   Chung, S I ^a   Park, H J ^a  

^a Dept Immunol MOGAM Biotech R   (South Korea)

Author keywords

H. pylori; Oral immunization; Poly(D,L lactide co glycolide) microparticles

Indexed keywords

BACTERIUM LYSATE; POLYGLACTIN;

ANIMAL EXPERIMENT; ARTICLE; CHRONIC GASTRITIS; FEMALE; HELICOBACTER PYLORI; IMMUNE RESPONSE; IMMUNIZATION; INFECTION PREVENTION; MOUSE; NONHUMAN; PARTICLE SIZE; PEPTIC ULCER; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HELICOBACTER PYLORI; IMMUNITY, MUCOSAL; IMMUNIZATION; LACTIC ACID; MICE; MICE, INBRED BALB C; PARTICLE SIZE; POLYGLYCOLIC ACID; POLYMERS;

EID: 0033547948     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00241-2     Document Type: Article

References (41)

1. Marshall B.J., Warren J.R. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1:1984;1311-1315.
2. Parsonnet J., Friedman G.D., Vandersteen D.P., Chang Y., Vogelman H.H., orentreich N., Sibley R.K. Helicobacter pylori infection and the risk of gastric carcinoma. New Eng. J. Med. 325:1991;1127-1132.
3. Bungnoli M., Bayeli P.F., Rappuoli R., Pennatini C., Figura N., Crabtree J.E. Inhibition of Helicobacter pylori urease by omeprazole. Eur. J. Gastroenterol. Hepatol. 5:1993;683-685.
4. Xia H.X., Daw M.A., Sant S., Beattie S., Keane C.T., O'Morain C.A. Clinical efficacy of triple theraphy in Helicobacter pylori-associated duodenal ulcer. Eur. J. Gastroenterol. Hepatol. 5:1993;141-144.
5. Van Zwet A.A., Thijs J.C., Oom J.A.J., Hoogeveen J., Duringshoff B.L. Failure to eradicate Helicobacter pylori in patients with metronidazole-resistant strains. Eur. J. Gastroenterol. Hepatol. 5:1993;185-186.
6. Michetti P., Wadstrom T., Lee A., Kreiss C., Blum A.L. Frontiers in Helicobacter pylori research: pathogenesis, host response, vaccine development and new therapeutic approaches. Eur. J. Gastroenterol. Hepatol. 8:1996;717-722.
7. Lee A. Vaccination against Helicobacter pylori. J. Gastroenterol. 31(Suppl. IX):1996;69-72.
8. Walker R.I. New strategies for using mucosal vaccination to achieve more effective immunization. Vaccine. 12:1994;387-400.
9. Czinn S.J., Nedrid J.G. Oral immunization against Helicobacter pylori. Infect. Immun. 59:1991;2359-2363.
10. Czinn S.J., Cai A., Nedrud J.G. Protection of germ-free mice from infection by Helicobacter felis after active oral or passive IgA immunization. Vaccine. 11:1993;637-642.
11. Nedrud J.G., Liang X.P., Hague N., Lamm M.E. Combined oral/nasal immunization protects mice from sendai virus infection. J. Immunol. 139:1987;3484-3492.
12. Michetti P., Corthesy-Theulaz I., Davin C., Haas R., Vaney A.-C., Heitz M., Bille J., Kraehenbuhl J.-P., Saraga E., Bulm A. Immunization of Balb/c mice against Helicobacter felis infection with Helicobacter pylori urease. Gastroenterology. 107:1994;1002-1011.
13. Di Tommaso A., Saletti G., Pizza M., Rappuoli R., Dougan G., Abrignani S., Douce G., De Magisris M.T. Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant. Infect. Immun. 64:1996;974-979.
14. Levine M.M., Kaper J.B., Black R.E., Clements M.L. New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. Microbiol. Rev. 47:1983;510-550.
15. Pizza M., Fontana M.R., Giuliani M.M., Domenighini M., Magagnoli C., Giunelli V., Nucci D., Hol W., Manetti R., Rappuoli R. A genetically detoxified derivative of heat-labile Escherichia coli enterotoxin induces neutralizing antibodies against the A subunit. J. Exp. Med. 80:1994;2147-2153.
16. Challacombe S.J., Rahman D., Jeffery H., Davis S.S., O'Hagan D.T. Enhanced secretory IgA and systemic IgG antibody responses after oral immunization with biodegradable microparticles containing antigen. Immunology. 76:1992;164-168.
17. O'Hagan D.T., Rahman D., Jeffery H., Sharif S., Challacombe S.J. Controlled release microparticles for oral immunization. Int. J. Pharm. 108:1994;133.
18. Maloy K.J., Donachie A.M., O'Hagan D.T., Mowat A.M. Induction of mucosal and systemic responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles. J. Immunol. 81:1994;661-667.
19. Wise D.L., Fellman R.D., Sanderson J.E., Wentworth R.L. Lactide/glycolide polymers. Description of the polymers used as surgical suture material, raw material for osteosynthesis and in sustained release forms of drugs. In: Gregoriadis G., editor. Drug carriers in medicine. London: Academic Press, 1979:237.
20. Furr B.J.A., Pharmacological studies with zoladex, a novel luteinizing hormone-releasing hormone analogue. In: Chisholm G.D., editor. Zoladex: a new treatment for prostatic cancer. Royal Society of Medicine international Congress and Symposium Series, 1987;125:1.
21. Thomasin C., Corradin G., Men Y., Merkle H.P., Gander B. Tetanus toxoid and synthetic malaria antigen containing poly(lactide)/poly(lactide-co-glycolide) microspheres: importance of polymer degradation and antigen release for immune response. J. Contr. Rel. 41:1996;131-145.
22. Kofler N., Ruedl C., Klima J., Recheis H., Bock G., Wick G., Wolf H. Preparation and characterization of poly-(D,L-lactide-co-glycolyde) and poly-(L-lactic acid) microspheres with entrapped pneumotropic bacterial antigens. J. Immunol. Meth. 192:1996;25-35.
23. Partidos C.D., Vohra P., Jones D.H., Farrar G.H., Steward M.W. Mucosal immunization with a measle virus CTL epitope encapsulated in biodegradable PLG microparticles. J. Immunol. Meth. 195:1996;135-138.
24. Eldridge J.H., Staas J.K., Meulbroek J.A., McGhee J.R., Tice T.R., Gilley R.M. Biodegradable microspheres as a vaccine delivery system. Mol. Immunol. 28:1991;287-294.
25. Jeffery H., Davis S.S., O'Hagan D.T. Preparation and characterization of poly(lactide-co-glycolide) microparticles: II. Protein entrapment by water-in oil-in water emulsion solvent evaporation. Pharm. Res. 10:1993;362-368.
26. Laemmli K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:1970;680-685.
27. Elson C.O., Ealding W., Lefkouritz J. A lavage technique allowing repeated measurements of IgA antibody in mouse intestinal secretions. J. Immunol. Meth. 67:1984;101-108.
28. Czerkinsky C.C., Nilsson L.A., Nygren H., Ouchterlony O., Tavkowski A. A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J. Immunol. Meth. 65:1983;109-121.
29. Coombes A.G.A., Lavelle E.C., Jenkins P.G., Davis S.S. Single dose, polymeric, microsphere-based vaccines: the influence of formulation conditions on the magnitude and duration of the immune response to a protein antigen. Vaccine. 14:1996;1429-1438.
30. Kim S.Y., Park H.J., Kim J.S., Yoem J.S., Jeong H.S., Moon H.M. Serodiagnosis of H. pylori infection in Korean patients using ELISA system. J. Gastroenterol. Hepatol. 11(Suppl. 1):1996;A26.
31. Forman D., Sitias F., Newell D.G. Geographic association of Helicobacter pylori antibody prevalence and gastric cancer mortality in rural China. Int. J. Cancer. 46:1990;608-611.
32. Lee A., Chen M. Successful immunization against gastric infection with Helicobacter species: use of a cholera toxin B subunit-whole-cell vaccine. Infect. Immunol. 62:1994;3594-3597.
33. Michetti M., Rossi M., Giannelli V., Giuliani M.M., Pizza M., Censini S., Covacci A., Massari P., Pagliaccia C., Manetti R., Telford J.L., Douce G., Dougan G., Rappuoli R., Ghiara P. Protection against Helicobacter pylori infection in mice by intragastric vaccination with H. pylori antigens is achieved using a non-toxic mutant of E. coli heat-labile enterotoxin (LT) as adjuvant. Vaccine. 16:1998;33-37.
34. O'Hagan D.T., Rahman D., McGee J.P., Jeffery H., Davies M.C., Williams P., Davis S.S. Biodegradable microparticles as controlled release antigen delivery systems. Immunology. 73:1991;239-242.
35. Alonso M., Gupta R.K., Min C., Siber G.R., Langer R. Biodegradable microspheres as controlled-release tetanus toxoid delivery systems. Vaccine. 12:1994;299-306.
36. Challacombe S.J., Rahman D., O'Hagan D.T., Common mucosal immune responses following oral immunization with biodegradable microparticles. Clin. Immunol. Immunopathol., 1995:76, Abstract 101.
37. Jani C., McCarthy E., Fluorence T. Nanosphere and microsphere uptake via Peyer's patch: observation of the rate of uptake in the rat after a single oral dose. Int. J. Pharm. 86:1992;239-246.
38. Tabata Y., Inoue Y., Ikada Y. Size effect on systemic and mucosal immune responses induced by oral administration of biodegradable microspheres. Vaccine. 14:1996;1677-1685.
39. Czerkinsky C., Svennerholm A.M., Quiding M., Johnson R., Holmgren J. Antibody-producing cells in peripheral blood and salivary glands after oral cholera vaccination of humans. Infect. Immun. 59:1991;996-1001.
40. Gomez-Duarte O.S., Lucas B., Yan Z.-X., Panthel K., Haas R., Meyer T.F. Protection of mice against gastric colonization by Helicobacter pylori by single oral dose immunization with attenuated Salmonella typhimurium producing urease subunits A and B. Vaccine. 16:1998;460-471.
41. Lee A., O'Rourke J., De Ungria M.C., Robertson B., Daskalopoulos G., Dixon M.F. A standardized mouse model of Helicobacter pylori infection: introducing the Sydney strain. Gastoenterology. 112:1997;1365-1397.